Literature DB >> 11064356

Surgical therapy for distant metastases of malignant melanoma.

T Meyer1, S Merkel, J Goehl, W Hohenberger.   

Abstract

BACKGROUND: Manifestation of distant metastases in melanoma patients commonly indicates a poor prognosis. The aim of the current study was to examine the role of surgical treatment in these patients.
METHODS: Data from 444 patients with distant melanoma metastases were gathered prospectively from January 1978 through December 1997. Characteristics of the primary tumor, time until the first occurrence of distant metastases, frequency and site of distant metastases, surgical therapy, and survival were evaluated by univariate and multivariate analyses.
RESULTS: Histology, Breslow thickness, Clark level, and pT and pN categories (UICC 1997) significantly influenced the median interval from initial diagnosis to manifestation of distant metastases. The most common single localization was the lung (n = 83), followed by distant lymph node (n = 79), and skin metastases (n = 51). One hundred seventy-four patients received surgical treatment (39%) and 111 (25%) patients received surgical treatment with curative resection (R0, UICC 1997), most frequently in distant lymph node or skin metastases (57% and 59%, respectively). Median survival time and 2-year survival rate for all patients were 7 months and 15.8%, respectively, 17 months and 36.1% following curative resection, 6 months and 12.7% after incomplete resection (n = 63) (P < 0.0001). Conservatively treated patients survived for a median of only 4 months with a 2-year survival of 8.1%. Multivariate survival analysis showed localization of the primary tumor (head/neck/trunk vs. extremities), the number of involved sites, and surgical therapy to be independent prognostic factors.
CONCLUSIONS: Surgical therapy of distant metastases was most beneficial when complete removal of metastatic tissue was achieved. Selection of patients for surgical excision should be determined by individual patient indications. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Year:  2000        PMID: 11064356     DOI: 10.1002/1097-0142(20001101)89:9<1983::aid-cncr15>3.3.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  25 in total

1.  Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I).

Authors:  J Harrison Howard; John F Thompson; Nicola Mozzillo; Omgo E Nieweg; Harald J Hoekstra; Daniel F Roses; Vernon K Sondak; Douglas S Reintgen; Mohammed Kashani-Sabet; Constantine P Karakousis; Brendon J Coventry; William G Kraybill; B Mark Smithers; Robert Elashoff; Stacey L Stern; Alistair J Cochran; Mark B Faries; Donald L Morton
Journal:  Ann Surg Oncol       Date:  2012-05-31       Impact factor: 5.344

Review 2.  Therapy for metastatic melanoma: the past, present, and future.

Authors:  Laura Finn; Svetomir N Markovic; Richard W Joseph
Journal:  BMC Med       Date:  2012-03-02       Impact factor: 8.775

3.  Impact of 2-deoxy-2[F-18]fluoro-D-glucose Positron Emission Tomography on the management of patients with advanced melanoma.

Authors:  Marion T Harris; Salvatore U Berlangieri; Jonathan S Cebon; Ian D Davis; Andrew M Scott
Journal:  Mol Imaging Biol       Date:  2005 Jul-Aug       Impact factor: 3.488

4.  Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.

Authors:  Danielle M Bello; Katherine S Panageas; Travis Hollmann; Alexander N Shoushtari; Parisa Momtaz; Paul B Chapman; Michael A Postow; Margaret K Callahan; Jedd D Wolchok; Mary S Brady; Daniel G Coit; Charlotte E Ariyan
Journal:  Ann Surg Oncol       Date:  2019-12-17       Impact factor: 5.344

5.  Malignant melanoma of the skin: long-term follow-up and time to first recurrence.

Authors:  Annika M Hohnheiser; Olaf Gefeller; Jonas Göhl; Gerold Schuler; Werner Hohenberger; Susanne Merkel
Journal:  World J Surg       Date:  2011-03       Impact factor: 3.352

6.  Surgical resection of malignant melanoma metastatic to the pancreas: case series and review of literature.

Authors:  Jatinder Goyal; Evan J Lipson; Neda Rezaee; Barish H Edil; Rich Schulick; Christopher L Wolfgang; Ralph H Hruban; Emmanuel S Antonarakis
Journal:  J Gastrointest Cancer       Date:  2012-09

Review 7.  Treatment of metastatic malignant melanoma.

Authors:  Ehab Atallah; Lawrence Flaherty
Journal:  Curr Treat Options Oncol       Date:  2005-05

8.  [Malignant melanoma].

Authors:  J Göhl; W Hohenberger; S Merkel
Journal:  Chirurg       Date:  2009-06       Impact factor: 0.955

9.  MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome.

Authors:  J C Hassel; A Sucker; L Edler; H Kurzen; I Moll; C Stresemann; K Spieth; C Mauch; K Rass; R Dummer; D Schadendorf
Journal:  Br J Cancer       Date:  2010-08-24       Impact factor: 7.640

10.  [Metastatic malignant choroidal melanoma: a case report about 18 years with palliative operative treatment].

Authors:  T Prietzel; I Haferkorn; A Macher; E Schumann; G von Salis-Soglio; T Aigner
Journal:  Orthopade       Date:  2009-03       Impact factor: 1.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.